Biopharma and data — Total Revenue
Guardant Health Biopharma and data — Total Revenue decreased by 1.9% to $52.98M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.8%, from $45.38M to $52.98M. Over 2 years (FY 2023 to FY 2025), Biopharma and data — Total Revenue shows an upward trend with a 24.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing demand for the company's research services and data insights among pharmaceutical partners, suggesting successful monetization of the company's genomic platform. A decrease may signal reduced R&D spending by biopharma clients or increased competition in the clinical trial support market.
Detailed definition
This metric represents the total gross revenue generated from partnerships, clinical trial support, and data licensing s...
Peer comparison
Comparable to 'Biopharma Services' or 'Research Collaboration Revenue' reported by other precision medicine and diagnostic companies that offer data-driven insights to the pharmaceutical industry.
gh_segment_biopharma_and_data_total_revenueHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $34.09M | $34.09M | $34.09M | $34.09M | $37.59M | $43.93M | $46.55M | $49.51M | $45.38M | $56.02M | $54.73M | $54.01M | $52.98M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +10.3% | +16.9% | +5.9% | +6.4% | -8.4% | +23.5% | -2.3% | -1.3% | -1.9% |
| YoY Change | — | — | — | — | +10.3% | +28.9% | +36.6% | +45.2% | +20.7% | +27.5% | +17.6% | +9.1% | +16.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Guardant Health's biopharma and data — total revenue?
- Guardant Health (GH) reported biopharma and data — total revenue of $52.98M in Q1 2026.
- How has Guardant Health's biopharma and data — total revenue changed year-over-year?
- Guardant Health's biopharma and data — total revenue increased by 16.8% year-over-year, from $45.38M to $52.98M.
- What is the long-term trend for Guardant Health's biopharma and data — total revenue?
- Over 2 years (2023 to 2025), Guardant Health's biopharma and data — total revenue has grown at a 24.1% compound annual growth rate (CAGR), from $136.35M to $210.13M.
- What does biopharma and data — total revenue mean?
- Total revenue earned from biopharmaceutical partnerships, clinical trial support, and data licensing services.